HighMark Wealth Management’s Viking Therapeutics VKTX Stock Holding History

HighMark Wealth Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$173K	Hold	5,310	–	–	0.07%	82
2025 Q4	$187K	Hold	5,310	–	–	0.08%	80
2025 Q3	$140K	Sell	5,310 -1,350	-20%	-$40.3K	0.06%	96
2025 Q2	$176K	Buy	6,660 +2,000	+43%	+$52.6K	0.09%	81
2025 Q1	$113K	Buy	4,660 +400	+9%	+$12.6K	0.07%	83
2024 Q4	$171K	Buy	4,260 +1,260	+42%	+$71.8K	0.1%	59
2024 Q3	$190K	Buy	+3,000	New	+$176K	0.1%	69

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

HighMark Wealth Management's VKTX Position: Q1 2026 in Review

HighMark Wealth Management held its Viking Therapeutics (VKTX) position steady in Q1 2026 at 5,310 shares worth $173K. The position accounts for 0.07% of the portfolio, ranked #82.

HighMark Wealth Management first reported a position in VKTX in Q3 2024 and has held it in 7 quarters since. The position peaked at $190K in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

HighMark Wealth Management held 5,310 shares of Viking Therapeutics worth $173K as of Q1 2026.
HighMark Wealth Management left its Viking Therapeutics share count unchanged in Q1 2026.
Viking Therapeutics made up 0.07% of HighMark Wealth Management's portfolio in Q1 2026, its #82 holding.
HighMark Wealth Management first reported a position in Viking Therapeutics in Q3 2024 and has held it in 7 quarters since.
HighMark Wealth Management's Viking Therapeutics position peaked at $190K in Q3 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on HighMark Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.